Clinical Trials
35 trialsA Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Collection of Tissue Samples for Cancer Research
National Institutes of Health Clinical Center (CC)
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Washington University School of Medicine
TAPUR
American Society of Clinical Oncology
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
AbbVie
FOCUS
Ohio State University Comprehensive Cancer Center
LONGEVITI
University of Alberta
inMMyCAR
Kelonia Therapeutics, Inc.
CER
Cancer Support Community, Research and Training Institute, Philadelphia
SURGE
Colorado State University
Discontinuation Study
University College Cork
SELECT-CAR-NK
Essen Biotech
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
POSBIO-CRC
AC Camargo Cancer Center
LIBERATE
University Health Network, Toronto
DETERMINE
Cancer Research UK
e-Motion : Promoting Emotion Regulation in Chronic Cancer
Université Libre de Bruxelles
VRd MM Fibrate
Tanta University
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Monash University
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Barbara Ann Karmanos Cancer Institute
CARLOTTA01
Technische Universität Dresden
CARTIER
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
AmbuSpé
University Hospital, Toulouse
Survivorship
University of Modena and Reggio Emilia
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
RATIONALISE
Monash University
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology